{
    "clinical_study": {
        "@rank": "41687", 
        "arm_group": [
            {
                "arm_group_label": "AGN-214868 Dose 1", 
                "arm_group_type": "Experimental", 
                "description": "AGN-214868 Dose 1 given as injections into the area of pain on Day 1."
            }, 
            {
                "arm_group_label": "AGN-214868 Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "AGN-214868 Dose 2 given as injections into the area of pain on Day 1."
            }, 
            {
                "arm_group_label": "AGN-214868 Placebo (Vehicle)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1."
            }, 
            {
                "arm_group_label": "AGN-214868 Dose 3", 
                "arm_group_type": "Experimental", 
                "description": "AGN-214868 Dose 3 given as injections into the area of pain on Day 1."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a safety and efficacy study of AGN-214868 in patients with postherpetic neuralgia\n      (PHN)."
        }, 
        "brief_title": "A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Neuralgia, Postherpetic", 
        "condition_browse": {
            "mesh_term": [
                "Neuralgia", 
                "Neuralgia, Postherpetic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Postherpetic neuralgia with pain present for at least 9 months\n\n        Exclusion Criteria:\n\n          -  Active herpes zoster skin rash\n\n          -  Anticipated treatment for postherpetic neuralgia during the first 3 months of the\n             study, including oral and topical medications, acupuncture, spinal cord stimulation,\n             transcutaneous nerve stimulation (TNS), or trigger point injection\n\n          -  Anticipated treatment with pain medication for the treatment of postherpetic\n             neuralgia during the first 3 months of the study\n\n          -  Use of capsaicin treatment for postherpetic neuralgia within 6 months, or anticipated\n             use during the first 3 months of the study\n\n          -  Use of botulinum toxin of any serotype for any reason within 6 months, or anticipated\n             use during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "270", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678924", 
            "org_study_id": "214868-007", 
            "secondary_id": "2012-002240-24"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "AGN-214868 Dose 1", 
                    "AGN-214868 Dose 2", 
                    "AGN-214868 Dose 3"
                ], 
                "description": "AGN-214868 given as injections into the area of pain on Day 1.", 
                "intervention_name": "AGN-214868", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AGN-214868 Placebo (Vehicle)", 
                "description": "AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.", 
                "intervention_name": "AGN-214868 Placebo (Vehicle)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 13, 2014", 
        "link": {
            "description": "More information", 
            "url": "http://www.allerganclinicaltrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boulder", 
                        "country": "United States", 
                        "state": "Colorado"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vienna", 
                        "country": "Austria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brno", 
                        "country": "Czech Republic"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Katowice", 
                        "country": "Poland"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Austria", 
                "Czech Republic", 
                "Germany", 
                "Poland"
            ]
        }, 
        "number_of_arms": "4", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Average Pain Intensity Score", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678924"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Average Pain Intensity Score Responders", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Change from Baseline in Maximal Area of Spontaneous Pain", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Change from Baseline in Area of Allodynia", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Change from Baseline in Evoked Pain Score in the Area of Allodynia", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}